Why Do Foreign Biotech and Pharma Companies Struggle to Hire US Leadership?
- Philip Lamb
- Jul 7
- 8 min read
In 2025, five European pharmaceutical companies committed roughly 173 billion dollars to United States operations. AstraZeneca announced 50 billion. Roche announced 50 billion. GSK committed 30 billion. Novartis announced 23 billion. Sanofi committed 20 billion. Those are the companies' own public announcements, made within a single year, and they represent one of the largest waves of foreign direct investment into American life sciences manufacturing and research in history.
Every one of those dollars needs American leadership to spend it well. A new fill and finish plant needs a site head. A new research campus needs an American R&D leader who can recruit against Boston and San Diego. A new US commercial operation needs a general manager who understands American payers, American distribution, and the FDA. And here is the part almost nobody at those headquarters wants to hear: the leadership those investments require does not exist anywhere on their current org charts.
The struggle foreign biotech and pharma companies have hiring US leadership is not a talent shortage. The talent is here. The struggle is that foreign headquarters run the US hire by home country rules, in a market that does not follow them. We watch it happen at every size, from a 100 billion dollar pharmaceutical company to a 40 million euro diagnostics firm making its first American move.
PRL International is a retained executive search firm serving Pittsburgh and Western Pennsylvania, specializing in senior-level placements in manufacturing, energy, life sciences, and mid-market companies, with a dedicated practice helping foreign companies build their first US leadership teams. This post explains where the life sciences version of that first hire goes wrong, what the 2025 investment wave does to the market, and what the companies that get it right do differently. It is part of our larger guide on how a foreign company sets up and staffs its first US operation.
Why Is the US Life Sciences Talent Market So Hard for a Foreign Company to Read?
The US life sciences talent market is hard for a foreign company to read because it is not one national market but a handful of competing regional clusters, each with its own compensation norms, equity expectations, and candidate behavior, and none of them work like the market around a European or Asian headquarters. Boston and Cambridge, the San Francisco Bay Area, San Diego, the New Jersey pharmaceutical corridor, and the Philadelphia cell and gene therapy hub each price the same title differently, and a package that wins in one cluster loses in another.
Consider what a foreign headquarters is used to. In Basel, Paris, or Osaka, there is usually one dominant life sciences employment center, a national compensation convention, long notice periods that slow everything down, and a professional culture where the company's name carries the recruiting conversation. Every one of those assumptions breaks on contact with the American market.
Factor | Home market | US life sciences market |
Talent geography | One dominant national center | Four or five competing clusters, each with its own pay norms |
Compensation | Base-heavy, modest bonus | Base is one layer; bonus, equity, and long-term incentives decide the offer |
Candidate mobility | Long notice periods, slow moves | At-will employment; a strong candidate can be gone in two weeks |
Regulatory fluency | EMA, PMDA, national agencies | FDA, and the FDA alone; agency experience does not transfer |
Employer brand | Known name, opens doors | Unknown name; the opportunity has to sell itself |
The regulatory line deserves its own paragraph, because it is the one foreign life sciences companies most consistently underweight. A quality or regulatory leader who has spent a career navigating the EMA does not arrive fluent in FDA. Submission strategy, inspection culture, warning letter dynamics, and the FDA's quality system expectations are a distinct body of knowledge, and the transition to QMSR has only raised the bar, a shift we covered in detail in what makes executive search for a medical device company different. The candidates who carry real FDA scar tissue know exactly what it is worth, and they price it accordingly.
Geography compounds the difficulty. The obvious move is to plant the US operation in Boston or San Diego, and for some science driven builds that is right. But those are also the two most expensive leadership markets in American life sciences, where a mid-cap foreign company bids against Pfizer, Moderna, and a hundred venture-funded biotechs for the same vice president. The less obvious markets, including the Philadelphia pharma and healthcare corridor and the medical device and life sciences base in Western Pennsylvania, offer real depth at a materially different price. Reading that trade correctly is itself a leadership market judgment most foreign boards have no basis to make alone.
What Does the 2025 Pharma Investment Wave Mean for US Leadership Hiring?
The 2025 pharma investment wave means that five European pharmaceutical companies alone committed roughly 173 billion dollars to US manufacturing and research operations in a single year, and every new site, plant, and expanded footprint in that wave needs American leadership those companies do not currently employ. That is the demand side of the market you are about to hire in, and it is the most crowded it has been in decades.
Think through what those announcements mean operationally. A 50 billion dollar commitment is not one facility. It is a network of manufacturing sites, research expansions, and supply chain moves spread across multiple states, each needing a site leader, a quality head, an operations director, and a bench below them. Multiply that across five companies, then add the American firms expanding at the same time for the same tariff and supply chain reasons, and you get a compressed, competitive market for exactly the FDA-fluent operational leaders every one of those projects requires.
For the mid-sized foreign biotech or diagnostics company, this is the part that matters: you are not competing for US leadership against companies your own size. You are competing against AstraZeneca's project budget. When a plant quality director in New Jersey or a biologics operations VP in North Carolina has five live approaches in their inbox, the unknown foreign company with the slow, headquarters-driven hiring process is the easiest one to ignore. The investment wave did not create the difficulty foreign companies have hiring US leadership. It raised the price of every mistake.
What Does the Wrong First US Hire Cost a Foreign Life Sciences Company?
The wrong first US hire costs a foreign life sciences company anywhere from 30 percent of the executive's first year earnings to 15 times base salary depending on which study you use, and for a first country leader the true number sits at the top of that range because the entire expansion depends on one person. The studies disagree on the multiple. None of them disagree on the direction.
We walked through why those estimates diverge so widely, and which costs stay invisible on a P&L, in what it really costs to make the wrong executive hire. Leadership IQ's research adds the base rate: 46 percent of new hires fail within 18 months, and senior hires are not exempt. Now put that arithmetic in a life sciences frame. A failed US general manager does not just cost severance and a second search. It costs a year of the FDA relationship. It costs the first wave of American hires, who joined the leader and leave with them. In a regulated industry it can cost an inspection outcome. For a foreign company on a board-approved expansion timeline, the wrong first hire routinely sets the US entry back two years, and some boards never approve the second attempt.
In more than 30 years of retained search, we have found that the foreign expansions that stall in year one almost always share the same first move: the company sent a trusted home office executive to run the United States instead of hiring an American leader who already knew the market. The expatriate is loyal and knows the products, but they are learning the FDA, American compensation, and American customers at the same time, on the company's most expensive tuition plan. The pattern is common enough that we wrote the German version of it in how a German company hires senior leaders for its US expansion, and the biotech version differs only in how fast the regulatory clock punishes it.
"If you know the enemy and know yourself, you need not fear the result of a hundred battles." Sun Tzu, The Art of War
Sun Tzu's line survives because it names the two failures at once. Foreign life sciences companies usually know themselves. What they do not know is the terrain: the American talent market, its prices, its speed, and its rules. The first US hire is the moment both kinds of knowledge get tested.
How Should a Foreign Biotech or Pharma Company Hire Its First US Leaders?
A foreign biotech or pharma company should hire its first US leaders by settling decision rights before the search opens, pricing the package against the specific US cluster it is entering rather than a national average, and requiring FDA fluency as a hard specification rather than a detail the leader can learn on the job. Those three decisions, made before anyone reviews a resume, separate the expansions that compound from the ones that stall.
Decision rights come first because the best American candidates screen for them ruthlessly. Within the first conversation, a strong US life sciences executive will ask who approves their hires, their pricing, and their regulatory strategy. If the honest answer is a committee at headquarters seven time zones away, the best candidates withdraw politely and take one of their other offers, and you will spend the search meeting only the people who had no other offers. Autonomy, defined in writing before the search opens, is the single cheapest thing a foreign board can do to raise the quality of its candidate pool.
Pricing comes second. The offer has to be built for the cluster you are entering, not translated from home country conventions. A base-heavy European package reads as a pay cut to an American executive whose last three offers all carried bonus targets and long-term incentives. The good news is that the company that prices honestly for the market it is actually in, especially outside the two or three trophy clusters, often pays less in total than the company that overpays in Boston to compensate for everything else it got wrong.
Regulatory fluency comes third, and it is the specification we most often have to defend to a foreign board. The instinct is to prioritize product knowledge and company culture and assume the American regulatory layer can be staffed underneath the leader. In a life sciences business it runs exactly backwards: FDA credibility at the top is what lets everything underneath move fast. This is the same logic that governs C-suite searches for regulated manufacturers generally, which we detailed in what C-suite search looks like for a Pittsburgh medical device manufacturer.
Run those three decisions through a search process built for a company without a US network and the odds change completely. That is the specific gap our international executive search practice exists to close: a foreign company entering the American market does not need a bigger brand on the search, it needs someone who knows both the American talent terrain and the way a foreign headquarters actually makes decisions, and can translate between the two before the translation failures become hiring failures.
The 173 billion dollars is already committed. The plants are being announced state by state. The only open question is which foreign companies will put American leadership in place fast enough to make their share of it pay, and every quarter spent running the search by home rules is a quarter their competitors spend hiring.
If you are ready to fill a senior role or want to talk through your search, reach out at prlinternational.com/contact
Want to know what questions to ask before hiring a search firm? Download the free 7-Question Guide: https://prl-proposal.vercel.app/guide
Comments